Review Article

MicroRNAs Regulate Function in Atherosclerosis and Clinical Implications

Zhaoyi Li , 1 Yidan Zhao , 1 Sei Suguro , 2 and Rinkiko Suguro 1

1State Key Laboratory of Quality Research in Chinese Medicine, Macau University of Science and Technology, Avenida Wai Long, Taipa, Macau SAR, China
2Faculty of Medicine, School of Pharmacy, The Chinese University of Hong Kong, Shatin New Territories, Hong Kong SAR, China

Correspondence should be addressed to Rinkiko Suguro; rsuguro@must.edu.mo

Received 27 April 2022; Revised 5 July 2023; Accepted 10 August 2023; Published 29 August 2023

Academic Editor: Ihtisham Bukhari

Background. Atherosclerosis is considered the most common cause of morbidity and mortality worldwide. Athermanous plaque formation is pathognomonic of atherosclerosis. The main feature of atherosclerosis is the formation of plaque, which is inseparable from endothelial cells, vascular smooth muscle cells, and macrophages. MicroRNAs, a small highly conserved noncoding ribonucleic acid (RNA) molecule, have multiple biological functions, such as regulating gene transcription, silencing target gene expression, and affecting protein translation. MicroRNAs also have various pharmacological activities, such as regulating cell proliferation, apoptosis, and metabolic processes. It is noteworthy that many studies in recent years have also proved that microRNAs play a role in atherosclerosis.

Methods. To summarize the functions of microRNAs in atherosclerosis, we reviewed all relevant articles published in the PubMed database before June 2022, with keywords “atherosclerosis,” “microRNA,” “endothelial cells,” “vascular smooth muscle cells,” “macrophages,” and “cholesterol homeostasis,” briefly summarized a series of research progress on the function of microRNAs in endothelial cells, vascular smooth muscle cells, and macrophages and atherosclerosis. Results and Conclusion. In general, the expression levels of some microRNAs changed significantly in different stages of atherosclerosis pathogenesis; therefore, MicroRNAs may become new diagnostic biomarkers for atherosclerosis. In addition, microRNAs are also involved in the regulation of core processes such as endothelial dysfunction, plaque formation and stabilization, and cholesterol metabolism, which also suggests the great potential of microRNAs as a therapeutic target.

1. Introduction

According to statistics, as of 2019, an average of nearly 18 million people died of cardiovascular diseases every year, accounting for 32% of the global death toll. Atherosclerosis (AS) is the leading cause of death from cardiovascular diseases worldwide [1]. AS refers to a type of chronic blood disease in which a large amount of fat or cholesterol deposits on the walls of blood vessels and arteries, forming atherosclerotic plaques, resulting in reduced blood flow and blocked blood vessels. There are no obvious symptoms in the early stage of AS, but when the late symptoms do appear, the blood flow in the lumen is narrowed, and the blood flow is reduced, causing myocardial ischemia and hypoxia, and in severe cases, myocardial infarction, arrhythmia, and even sudden death [2]. The pathological mechanism of AS is complex, starting from the damaged intima, and the formation of plaques is also in the intima. In the early stage of the lesion, low-density lipoprotein (LDL) particles accumulate in the intima and are oxidized to oxidized LDL, causing an inflammatory response. Subsequently, proinflammatory monocytes bind to adhesion factors of endothelial cells, promoting the migration of monocytes to the arterial wall, where monocytes mature into macrophages in the intima. In the intima, macrophages transform into foam cells by engulfing lipoprotein particles, which further collect fat, cholesterol, and other substances. In the middle and late stages of the disease, the smooth muscle cells located in the media also enter the intima under the action of the medium produced by the aggregation of leukocytes, and proliferate, and accumulate in the arterial wall. As fat, cholesterol, and large amounts of cellular debris accumulate in the intima, plaques eventually form, which resemble “porridge.”
With the increase of the plaque, some plaques are unstable and detached or are too large to split, causing blood vessel blockage and thrombus formation, which is also the main reason for the high mortality rate of AS \[3\]. Furthermore, the developmental, progression, and formation of clinically relevant atherosclerotic plaques consist of endothelial cells, vascular smooth muscle cells, and macrophages \[4\]. In short, vascular smooth muscle cells accumulate and aggregate in susceptible sites, resulting in dense cell arrangement and intima thickening, promoting endothelial cell activation and producing platelet-derived growth factor. With the stimulation of a large number of cytokines, the production of lipoproteins, proteoglycans, and fibronectin is promoted. As the retained lipoproteins are taken up by macrophages and vascular smooth muscle cells, lipid uptake and foam cell formation are enhanced, thereby accelerating the progression of the lesion \[5\].

MicroRNAs, also known as miRNAs or miRs, were first discovered in 1993 in Caenorhabditis elegans (C. elegans) \[6, 7\]. MicroRNAs are a class of small noncoding ribonucleic acid (RNA) regulatory molecules with a length of about 18–25 nucleotides, widely present in mammalian cells and body fluids, and involved in posttranscriptional regulation of gene expression and protein translation \[8, 9\]. Most mature microRNAs start from the initial primary transcription product primary microRNA (pri-miRNA), and pri-miRNA is cleaved by RNase III Drosha enzyme in the nucleus to become a single-stranded RNA precursor microRNA (pre-miRNA), and then the pre-miRNA is transported to the cytoplasm, where it is further processed into mature miRNA by RNase III Dicer \[10\]. Since the discovery of microRNAs, a variety of complex cellular events involved in it have been reported one after another \[11\]. For example, embryonic development \[12\], cell proliferation and apoptosis \[13\], and immune response \[14\], etc. At the same time, miRNAs are also involved in the regulation of many diseases, such as cancer \[15\], central nervous system diseases \[16\], infectious diseases \[17\], and diabetes \[18\]. Furthermore, microRNAs are required for the normal development of the cardiovascular system. MicroRNAs affect the development of AS by regulating the proliferation, adhesion, and endothelial dysfunction of endothelial cells, intervening in the accumulation of cholesterol mediated by macrophages and the formation of foam cells, and regulating the proliferation, migration, and inflammatory response of vascular smooth muscle cells (Figure 1) \[7–9, 19–21\].

Here, we systematically summarize the regulation mechanism of microRNAs on endothelial cells, vascular smooth muscle cells, macrophages, and cholesterol balance in the pathological process of AS and elaborate on the potential of microRNAs as clinical diagnostic biomarkers of AS, as well as future challenges, to provide a reference for researchers exploring related fields.

2. MicroRNAs Regulate Endothelial Cells

The abnormal function of endothelial cells is the initial stage of AS. Accumulating evidence indicates that endothelial dysfunction triggers an inflammatory response that drives the occurrence, development, and even rupture of atherosclerotic plaques and ultimately promotes the pathological development of AS \[19, 22\]. Some microRNAs have positive effects
miR-107 Promoted endothelial dysfunction Regulated an endothelial signaling hub and downregulated a network of eNOS activators [27]

miR-217 Promoted endothelial dysfunction Inhibited NF-κB signaling pathway by targeting NEMO protein [24]

miR-181a-3p Blocked blood vessel inflammation Inhibited NF-κB signaling pathway by targeting TAB2 protein [24]

miR-181a-5p Blocked blood vessel inflammation Inhibited NF-κB signaling pathway by targeting NEMO protein [24]

miR-155 Promoted endothelial cells autophagic activity Inhibited Rheb-mediated mTOR/P70S6kinase/4EBP1 signaling pathway [19]

miR-200b-3p Promoted endothelial cells apoptosis Promoted oxidative stress-induced cell apoptosis by targeting HDAC4 [29]

miR-107 Inhibited inflammatory response and endoplasmic reticulum stress of vascular endothelial cells Regulated notch 1 signaling pathway [26]

miR-520c-3p Inhibited vascular endothelium dysfunction Regulated AKT and NF-κB signaling pathway by targeting RELA protein [23]

miR-250b Inhibited endothelial cells inflammation Downregulated NF-κB p65-ICAM1/VCAM1 axis [25]

miR-125a-5p Promoted oxLDL-induced vascular endothelial cells pyroptosis Inhibited TET2 expression, resulting in DNA methylation, mitochondrial dysfunction, increasing ROS production, and activated NF-κB that induces activation of inflammasome and maturation, the release of proinflammatory cytokines [30]

miR-217 Inhibited TET2 expression, resulting in DNA methylation, mitochondrial dysfunction, increasing ROS production, and activated NF-κB that induces activation of inflammasome and maturation, the release of proinflammatory cytokines [28]

miR-107 Protects vascular endothelial cells against inflammatory responses, endoplasmic reticulum stress of vascular smooth muscle cells, inhibiting apoptosis and inflammatory response or promoting cell proliferation and migration (Table 2) [31]

Some microRNAs inhibit the proliferation and migration of vascular smooth muscle cells and slow down the progression of AS. For example, miR-192-5p targets the expression of ATG7 and regulates autophagy [32], MiR-214-3p acts by downregulating the expression of FOXO1 [33]. MiR-146b exerts its effect by downregulating the expression of Bag1 and MMP16 [34]. In addition, some microRNAs can also inhibit apoptosis and inflammatory responses, thereby alleviating AS. For instance, miR-17-5p has the effect of enhancing cell proliferation and repairing wounds and reduces apoptosis by upregulating SIRT7 expression and inhibiting p53 activation [35]. MiR-378a targeting IGF1 and TLR8 significantly inhibits inflammatory response [36]. MiR-128-1-5p inhibits the expression of inflammatory factors and apoptotic proteins by regulating the RMRP/miR-128-1-5P/Gadd45g signaling pathway [37]. Conversely, some microRNAs play the opposite role and accelerate AS deterioration. For example, both miR-183-5p and miR-488 can promote cell proliferation and migration by targeting myocyte enhancer factor 2C (MEF2B) [38, 39]. MiR-140-5p increases cell viability and inhibits in vitro cell proliferation and migration and by targeting myocyte enhancer factor 2C (MEF2B) [38, 39]. MiR-140-5p increases cell viability and inhibits in vitro cell proliferation and migration and by targeting myocyte enhancer factor 2C (MEF2B) [38, 39].


Vascular smooth muscle cells reside in the medial layer of the arterial wall and are responsible for regulating vascular tone [30]. In AS, vascular smooth muscle cells migrate from the intima to the intima to proliferate and deposit in large numbers, further invading the plaque, causing the plaque to be unstable and prone to fall off, causing blood vessel blockage [21]. MicroRNAs have also been found to be involved in the transfer from endothelial cells to vascular smooth muscle cells, inhibiting apoptosis and inflammatory response or promoting cell proliferation and migration (Table 2) [31].

MicroRNAs have also been found to be involved in the transfer from endothelial cells to vascular smooth muscle cells, inhibiting apoptosis and inflammatory response or promoting cell proliferation and migration (Table 2) [31].

TABLE 1: The effects and mechanisms of microRNAs in regulating endothelial cells.

<table>
<thead>
<tr>
<th>MicroRNAs</th>
<th>Effects</th>
<th>Mechanisms</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-125a-5p</td>
<td>Promoted oxLDL-induced vascular endothelial cells pyroptosis</td>
<td>Inhibited TET2 expression, resulting in DNA methylation, mitochondrial dysfunction, increasing ROS production, and activated NF-κB that induces activation of inflammasome and maturation, the release of proinflammatory cytokines</td>
<td>[28]</td>
</tr>
<tr>
<td>miR-181a-3p</td>
<td>Blocked blood vessel inflammation</td>
<td>Inhibited NF-κB signaling pathway by targeting TAB2 protein</td>
<td>[24]</td>
</tr>
<tr>
<td>miR-181a-5p</td>
<td>Blocked blood vessel inflammation</td>
<td>Inhibited NF-κB signaling pathway by targeting NEMO protein</td>
<td>[24]</td>
</tr>
<tr>
<td>miR-217</td>
<td>Promoted endothelial dysfunction</td>
<td>Regulated an endothelial signaling hub and downregulated a network of eNOS activators</td>
<td>[27]</td>
</tr>
<tr>
<td>miR-200b-3p</td>
<td>Promoted endothelial cells apoptosis</td>
<td>Promoted oxidative stress-induced cell apoptosis by targeting HDAC4</td>
<td>[29]</td>
</tr>
<tr>
<td>miR-107</td>
<td>Inhibited inflammatory response and endoplasmic reticulum stress of vascular endothelial cells</td>
<td>Regulated notch 1 signaling pathway</td>
<td>[26]</td>
</tr>
<tr>
<td>miR-520c-3p</td>
<td>Inhibited vascular endothelium dysfunction</td>
<td>Regulated AKT and NF-κB signaling pathway by targeting RELA protein</td>
<td>[23]</td>
</tr>
<tr>
<td>miR-250b</td>
<td>Inhibited endothelial cells inflammation</td>
<td>Downregulated NF-κB p65-ICAM1/VCAM1 axis</td>
<td>[25]</td>
</tr>
<tr>
<td>miR-155</td>
<td>Promoted endothelial cells autophagic activity</td>
<td>Inhibited Rheb-mediated mTOR/P70S6kinase/4EBP1 signaling pathway</td>
<td>[19]</td>
</tr>
</tbody>
</table>
4. MicroRNAs Regulate Macrophages

Macrophages are an important part of the human immune system and can phagocytose and clear cell debris, dead cells, and pathogens in vivo [43]. During AS, on the one hand, macrophages are responsible for processing a large amount of cholesterol and triglycerides, and simultaneously help to clear some inflammatory substances [44]. On the other hand, once LDL enters, cholesterol accumulates in the blood vessel wall, and macrophages absorb the cholesterol oxidized by their free radicals, eventually turning into foam cells, which are conducive to plaque formation [45]. Recently, the roles of microRNAs in macrophages have been focused on, affecting the pathological process of AS by regulating inflammatory response, cholesterol metabolism, and foam cell formation (Table 3) [21, 45]. MiR-204 downregulates NFATc3 expression and prevents the formation of foam cells and AS [46]. MiR-181a-3p/5p and miR-155-5p attenuate inflammatory responses, and delay plaque formation, thereby slowing AS [24, 47]. Some microRNAs prevent AS by promoting mitochondrial oxidative metabolism, reducing ROS production and necroptosis, and improving cell survival, such as miR-10a [48], miR-210 [49], and miR-383 [49]. In addition, miR-368a promotes reverse cholesterol transport through the CD47-SIRPα axis and hinders AS progression [50]. However, miR-155 activates the NLRP3 inflammasome by regulating the ERK1/2

<table>
<thead>
<tr>
<th>MicroRNAs</th>
<th>Effects</th>
<th>Mechanisms</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-204</td>
<td>Prevented foam cell formation</td>
<td>Upregulated NFATc3 to reduce SR-A and CD36 levels</td>
<td>[46, 52]</td>
</tr>
<tr>
<td>miR-181a-3p/5p</td>
<td>Delayed plaque formation</td>
<td>Reduced proinflammatory gene expression and macrophage infiltration</td>
<td>[24]</td>
</tr>
<tr>
<td>miR-155</td>
<td>Activated NLRP3 inflammasome</td>
<td>Blocking the ERK1/2 pathway</td>
<td>[51]</td>
</tr>
<tr>
<td>miR-10a</td>
<td>Promoted mitochondrial oxidative metabolism in macrophages</td>
<td>Promoted Dicer/miR-10a-dependent metabolic reprogramming</td>
<td>[48]</td>
</tr>
<tr>
<td>miR-210</td>
<td>Reduced ROS production and necroptosis</td>
<td>Upregulated the HIF-1α level</td>
<td>[49]</td>
</tr>
<tr>
<td>miR-383</td>
<td>Reduced energy consumption and increased cell survival</td>
<td>Blocked the targeting of Parg protein</td>
<td>[49]</td>
</tr>
<tr>
<td>miR-155-5p</td>
<td>Mitigated vascular inflammation</td>
<td>Stimulated CTRP12 production</td>
<td>[47]</td>
</tr>
<tr>
<td>miR-368a</td>
<td>Promoted reverse cholesterol transport</td>
<td>Reduced SIRPA expression</td>
<td>[50]</td>
</tr>
<tr>
<td>miR-216a</td>
<td>Activated telomerase</td>
<td>Inhibited the Smad3/NF-κB signaling pathway</td>
<td>[53]</td>
</tr>
</tbody>
</table>

NFATc3, nuclear factor of activated T cells; SR-A, the class A macrophage scavenger receptors; CD36, fatty acid translocase; NLRP3, NLR family pyrin domain containing 3; ERK1/2, extracellular signal-regulated protein kinase1/2; HIF-1α, hypoxia-inducible factor 1-α; CTRP12, C1q tumor necrosis factor-related protein 12; SIRPA, signal regulatory protein alpha; Smad3, suppressor of mothers against decapentaplegic 3; NF-κB, nuclear factor κB.

4 Oxidative Medicine and Cellular Longevity
pathway and aggravates AS [51]. MiR-216a activates telomerase by regulating the Smad3/NF-κB pathway and promotes AS development [50].

5. MicroRNAs Regulate Cholesterol Homeostasis

Cholesterol homeostasis is a key to lipid accumulation in atherosclerotic plaques and increases the risk and exacerbation of AS once the balance of cholesterol is disrupted [54]. In recent years, microRNAs have played key regulatory roles in lipid homeostasis and cholesterol homeostasis involved in AS development (Table 4) [44]. For example, miR-210-3p inhibited NF-κB activation, reducing lipid accumulation and inflammatory responses [55]. MiR-34a, miR-33-5p, and miR-21 inhibit the development of AS by reducing intestinal cholesterol, regulating cholesterol efflux, and preventing foam cell formation, respectively [54, 56, 57]. In addition, miR-33a/b promotes lipid droplet accumulation by inhibiting apoptosis and accelerates AS [58]. So far, the role of microRNA in cholesterol homeostasis in AS needs more research support.

6. MicroRNAs Therapeutic Potential for AS

As summarized above, numerous studies have demonstrated the roles of microRNAs in regulating various pathological mechanisms in AS. MicroRNAs play important roles in the dysregulation that affects endothelial integrity, the function of vascular smooth muscle cells, macrophage, and cellular cholesterol homeostasis, which drives the initiation and growth of an atherosclerotic plaque [63]. In recent years, more studies have investigated the potential of microRNAs as therapeutic targets or biomarkers in AS (Table 5) [64]. For instance, hsa-miR-654-5p and hsa-miR-409-3p are the potentially critical biomarkers for AS patients [65]. Low expression of miR-211-5p and miR-675-3p are associated with the poor prognosis of AS [66, 67]. Low expression of miR-191-3p, miR-933, and miR-425-3p are related to the peripheral circulation of patients with lipid metabolism disorders, mainly LDL [68]. Moreover, dysregulation of microRNAs has a role in vascular aging [69]. Although there are few clinical studies of microRNAs for AS treatment, a variety of microRNAs have been found to reduce atherosclerosis in preclinical animal models, and some of these microRNAs have entered clinical studies in other diseases. For example, miR-494 is used to treat ischemic stroke (NCT03577093). miR-33 for the treatment of metabolic syndrome (NCT02606812) and heart failure (NCT02997462). miR-44 for the treatment of intracranial atherosclerosis (NCT02308166). miR-210 for the treatment of angina (NCT05374694). miR-155 for the treatment of bladder cancer (NCT03591367). miR-181 for the treatment of psoriasis (NCT05683769). miR-29 for the treatment of shoulder and neck pain (NCT02534558). These pieces of evidence fully illustrate the feasibility of microRNA therapy.

Although there are currently no microRNA drugs approved for the treatment of AS, drug candidates are in clinical development and clinical trials. Candidate drugs for microRNA therapy are mostly concentrated in antisense oligonucleotides (anti-miRs), microRNA mimics, and microRNA inhibitors. Among them, anti-miRs are the reverse complementary sequences of mature microRNAs, which bind to endogenous microRNAs and inactivate them through steric blocking, thereby regulating the function of microRNAs [70, 71], such as miR-494, miR-33, miR-712, and miR-114. MicroRNA mimics are synthetic double-stranded microRNA fragments that regulate the post-translational function of microRNAs by specifically binding to target genes and inhibiting their transcription and translation [72], such as miR-210, miR-125a-5p, miR-29a-3p, miR-115, and miR-181a-3/5p. In addition, miRNA inhibitors are designed to have the reverse complementary strand of the target gene, and microRNAs affect the normal function of miRNA inhibitors by binding to the target site [73], such as miR-29 and miR-24-3p. Encouragingly, a handful of microRNA drug candidates have recently entered clinical trials. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases. For example, MRG-110, as an antisense oligonucleotide, has entered clinical studies in other diseases.

| Table 4: The effects and mechanisms of microRNAs in regulating cholesterol homeostasis. |
|---------------------------------|---------------------------------|---------------------------------|----------------------------------|
| MicroRNAs | Effects | Mechanisms | References |
| miR-210-3p | Reduced lipid accumulation and inflammatory response | Inhibited IGF2/IGF2R to inhibit CD36 and NF-κB expressions | [55] |
| miR-34a | Reduced intestinal cholesterol or fat absorption | Inhibited CYP7A1 and CYP8B1 | [54] |
| miR-33a/b | Promoted lipid droplet accumulation | Inhibited apoptotic cell clearance via an autophagy-dependent mechanism | [58–62] |
| miR-33-5p | Regulated cholesterol efflux | Regulated the miR-33-5p-ABCA1/CS axis | [57] |
| miR-21 | Influenced foam cell formation | Promoted p38-CHOP and JNK signaling pathway | [56] |

IGF2, insulin-like growth factor 2; IGF2R, insulin-like growth factor 2 receptor; CD36, fatty acid translocase; NF-κB, nuclear factor κB; CYP7A1, cholesterol 7α-hydroxylase; CYP8B1, sterol-12α hydroxylase; ABCA1, ATP-binding cassette transporter A1; CS, citrate synthase; p38-CHOP, p38- C/EBP homologous protein; JNK, c-Jun N-terminal kinase.
### Table 5: MicroRNAs as clinical biomarkers with therapeutic potential in the AS.

<table>
<thead>
<tr>
<th>MicroRNAs</th>
<th>Cellular process</th>
<th>Cell type</th>
<th>Down- or upregulated</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-654-3/5p</td>
<td>Apoptosis and inflammatory response</td>
<td>Endothelial cells</td>
<td>↓</td>
<td>[13, 77, 78]</td>
</tr>
<tr>
<td>miR-409-3p</td>
<td>Senescence</td>
<td>Endothelial cells</td>
<td>↑</td>
<td>[13, 79]</td>
</tr>
<tr>
<td>miR-933</td>
<td>Oxidative stress and inflammatory response</td>
<td>Endothelial cells</td>
<td>↑</td>
<td>[16, 80]</td>
</tr>
<tr>
<td>miR-122</td>
<td>Plaque stabilization</td>
<td>Endothelial cells</td>
<td>↑</td>
<td>[81, 82]</td>
</tr>
<tr>
<td>miR-92</td>
<td>Cholesterol buildup, inflammatory response</td>
<td>Endothelial cells</td>
<td>↓</td>
<td>[83]</td>
</tr>
<tr>
<td></td>
<td>Foam cell formation</td>
<td>Macrophages</td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-211-5p</td>
<td>Inflammatory response</td>
<td>Macrophages</td>
<td>↓</td>
<td>[14, 85]</td>
</tr>
<tr>
<td>miR-675-3p</td>
<td>Adipogenesis and glucose metabolic</td>
<td>Macrophages</td>
<td>↓</td>
<td>[15, 86, 87]</td>
</tr>
<tr>
<td>miR-16</td>
<td>Inflammatory response</td>
<td>Macrophages</td>
<td>↓</td>
<td>[88, 89]</td>
</tr>
<tr>
<td>miR-155</td>
<td>Foam cell formation and cholesterol efflux</td>
<td>Macrophages</td>
<td>↓</td>
<td>[90]</td>
</tr>
<tr>
<td>miR-191-3p</td>
<td>Platelet activation and fibrous cap thickening</td>
<td>Smooth muscle cells</td>
<td>↓</td>
<td>[16, 63, 91]</td>
</tr>
<tr>
<td>miR-425-3/5p</td>
<td>Migration, phenotypic transformation, and proliferation</td>
<td>Vascular smooth muscle cells</td>
<td>↓</td>
<td>[16, 92]</td>
</tr>
<tr>
<td>miR-34</td>
<td>Vascular aging and inflammatory response</td>
<td>Vascular smooth muscle cells and endothelial cells</td>
<td>↑</td>
<td>[93, 94]</td>
</tr>
<tr>
<td></td>
<td>Inflammatory response</td>
<td>Endothelial cells</td>
<td></td>
<td>[95]</td>
</tr>
<tr>
<td>miR-29</td>
<td>Vascular endothelial injury</td>
<td>Endothelial cells</td>
<td>↑</td>
<td>[96]</td>
</tr>
<tr>
<td></td>
<td>Proliferation and migration</td>
<td>Vascular smooth muscle cells and endothelial cells</td>
<td>↑</td>
<td>[97]</td>
</tr>
<tr>
<td>miR-21</td>
<td>Plaques vulnerability</td>
<td>Macrophages</td>
<td>↓</td>
<td>[98]</td>
</tr>
<tr>
<td></td>
<td>Proliferation and migration</td>
<td>Vascular smooth muscle cells</td>
<td></td>
<td>[99]</td>
</tr>
</tbody>
</table>

| MeF2A, myocyte enhancer factor 2A; ABCA1, ATP-binding cassette transporter A1; TIMP3, TIMP metalloproteinase inhibitor 3; ABCG1, ATP-binding cassette subfamily G member 1; IGF2, insulin like growth factor 2; Ninjurin 1, nerve injury-induced protein 1; CCL4, chemokine C-C-motif ligand 4; TNFRSF1A, tumor necrosis factor receptor superfamily member 1A; NLRP3, NLR family pyrin domain containing 3; NEMO, NF-κB essential modulator; TAB2, TGF-beta activated kinase 1-binding protein 2; LYPLA1, lysophospholipase 1; CDC7, cell division cycle 7; Bcl2L11, BCL-2 like protein 11; Impα3, importin-α3; VSMCs, vascular smooth muscle cells; ox-LDL, oxidized low-density lipoprotein. |

### Table 6: MicroRNAs therapeutic strategies in AS.

<table>
<thead>
<tr>
<th>Strategy</th>
<th>MicroRNA</th>
<th>Target genes</th>
<th>Effects in AS</th>
<th>Clinical status</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antisense oligonucleotide</td>
<td>miR-494</td>
<td>MeF2A</td>
<td>Promoted plaque stabilization</td>
<td>Preclinical</td>
<td>[100]</td>
</tr>
<tr>
<td>(anti-miRs)</td>
<td>miR-33</td>
<td>ABCA1</td>
<td>Decreased lipid accumulation</td>
<td>Preclinical</td>
<td>[101]</td>
</tr>
<tr>
<td></td>
<td>miR-712</td>
<td>TIMP3</td>
<td>Decreased endothelial inflammation</td>
<td>Preclinical</td>
<td>[102]</td>
</tr>
<tr>
<td></td>
<td>miR-144</td>
<td>ABCA1/ABCG1</td>
<td>Regulated cholesterol metabolism and endothelial dysfunction</td>
<td>Preclinical</td>
<td>[103, 104]</td>
</tr>
<tr>
<td></td>
<td>miR-92a</td>
<td>miR-92a</td>
<td>Regulated angiogenesis and ischemia</td>
<td>Phase I</td>
<td>[74]</td>
</tr>
<tr>
<td></td>
<td>miR-29b</td>
<td>miR-29b</td>
<td>Regulated extracellular matrix synthesis and fibrosis</td>
<td>Phase II</td>
<td>[75]</td>
</tr>
<tr>
<td></td>
<td>miR-132</td>
<td>miR-132</td>
<td>Improved cardiac function</td>
<td>Phase I</td>
<td>[76]</td>
</tr>
<tr>
<td>miR-210</td>
<td>IGF2</td>
<td></td>
<td>Attenuated lipid accumulation and inflammation</td>
<td>Recruiting</td>
<td>[55, 105, 106]</td>
</tr>
<tr>
<td>miR-125a-5p</td>
<td>Ninjurin 1</td>
<td></td>
<td>Attenuated vascular dysfunction</td>
<td>Preclinical</td>
<td>[107]</td>
</tr>
<tr>
<td></td>
<td>CCL4</td>
<td></td>
<td>Decreased ox-LDL</td>
<td>Preclinical</td>
<td>[108]</td>
</tr>
<tr>
<td>miR-29a-3p</td>
<td>TNFRSF1A</td>
<td></td>
<td>Suppressed proliferation, migration, and invasion of VSMCs</td>
<td>Preclinical</td>
<td>[109]</td>
</tr>
<tr>
<td>miR-155</td>
<td>NLRP3</td>
<td></td>
<td>Attenuated inflammatory response</td>
<td>Preclinical</td>
<td>[7, 110]</td>
</tr>
<tr>
<td>miR-181a-3p</td>
<td>NEMO</td>
<td></td>
<td>Inhibited vascular inflammation</td>
<td>Preclinical</td>
<td>[24, 111]</td>
</tr>
<tr>
<td>miR-181a-5p</td>
<td>TAB2</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>miR-29</td>
<td>LYPLA1</td>
<td></td>
<td>Promoted endothelial function</td>
<td>Preclinical</td>
<td>[112]</td>
</tr>
<tr>
<td></td>
<td>CDC7</td>
<td></td>
<td>Regulated VSMCs proliferation and migration</td>
<td>Preclinical</td>
<td>[97]</td>
</tr>
<tr>
<td></td>
<td>Bcl2L11</td>
<td></td>
<td>Prevented cell growth of VSMCs</td>
<td>Preclinical</td>
<td>[113]</td>
</tr>
<tr>
<td>miR-24-3p</td>
<td>Impα3</td>
<td></td>
<td>Inhibited the proliferation and migration of VSMCs</td>
<td>Preclinical</td>
<td>[114]</td>
</tr>
</tbody>
</table>

Oxidative Medicine and Cellular Longevity
we also expect these microRNAs to achieve positive results in the clinical treatment of AS.

7. Discussion

As mentioned earlier, AS, as the most common cause of high morbidity and mortality in the world, is viewed as the result of four major steps, including (1) the initiation of endothelial cells activation and inflammation; (2) the promotion of intimal lipoprotein deposition, retention, modification, and foam cell formation; (3) the progression of complex plaques by plaque growth, enlargement of the necrotic core, fibrosis, thrombosis, and remodeling; (4) the precipitation of acute events such as myocardial infarction, unstable angina, ventricular fibrillation, or sudden coronary death [5]. As we have seen, microRNAs play indispensable roles in various stages of AS progression. Interestingly, the regulatory effects of most microRNAs can slow down the development of AS. For example, miR-520c-3p, miR-181a-5p, miR-181a-3p, miR-250b, and miR-107 have been shown to regulate endothelial cell proliferation, injury, or inflammatory responses, thereby reducing endothelial dysfunction [24, 27–29], miR-204, miR-181a-3p/5p, miR-155-5p, miR-10a, miR-383, miR-368a, miR-210-3p, miR-34a, miR-33-5p and miR-21 delays plaque formation by regulating cholesterol metabolism, avoiding conversion of macrophages into foam cells [32, 33, 35–37, 39], miR-204, miR-181a-3p/5p, miR-155-5p, miR-10a, miR-210, miR-383, miR-368a, miR-210-3p, miR-34a, miR-33-5p, and miR-21 delays plaque formation by regulating cholesterol metabolism and avoiding conversion of macrophages into foam cells [24, 45, 48, 49, 51, 54, 55, 59, 60]. On the contrary, there are also a small number of microRNAs that can worsen the process of AS. For example, miR-217, miR-125a-5p, miR-200b-3p, and miR-155 cause damage to endothelial cells [20, 23, 25, 26], miR-183-5p, miR-488, miR-140-5p, and miR-1253 accelerate intravascular plaque shedding [34, 40–42], miR-155, miR-216a, and miR-33a/b promote cholesterol accumulation and accelerate foam cell and plaque formation [47, 49, 58]. Therefore, microRNA is very likely to be used as a potential biomarker in the clinical diagnosis of AS in addition to routine blood tests and imaging tests.

However, the role of microRNAs in AS is still being explored, and many questions still need to be answered to deepen our understanding. For example, the entry of exogenous microRNA may interfere with the normal regulatory mechanism in cells and cause side effects, adverse reactions, or immune responses [115–117], which may limit the therapeutic effect of microRNA and its safety issues. Additionally, since AS involves multiple cell types and signaling pathways, how to ensure that microRNAs target specific target cells or tissues to avoid affecting normal cells or tissues cannot be ignored. In this regard, many developers have tried using different delivery systems to improve the biodegradation and targeting of microRNAs in vivo [118]. For instance, Liu et al. [46] use nanodiamonds as delivery vehicles for microRNAs and implant them into induced pluripotent stem cells to promote the differentiation of induced pluripotent stem cells into cardiomyocytes and enhance the ability of damaged cardiomyocytes to recover cardiac function. Lolli et al. [119] use fibrin/hyaluronic acid (F/H) hydrogel to encapsulate microRNAs and implant subcutaneous damaged cartilage tissue and enhances the cartilage repair and regeneration function of endogenous cells. Based on nanoparticles and hydrogels, Li et al. [121] developed a new delivery system in which nanocarriers were encapsulated in injectable hydrogels, using this delivery system to deliver microRNAs to promote angiogenesis while reducing inflammation and effectively reduce the infarct size after myocardial infarction [122]. In addition, exosomes are another novel delivery system for microRNAs [123], which can improve the uptake of microRNAs by cells while promoting angiogenesis and wound healing [124]. However, the complex nanocarrier encapsulation process will inevitably cause off-target effects of microRNAs in vivo [125]. The charge properties of microRNAs affect their rate of release from hydrogels [120]. Treatment methods such as sonication and incubation with permeabilizers may cause exosomes to reorganize or deform and destroy the integrity of exosomes, thereby affecting the delivery efficiency of microRNAs [105, 124]. The solution to these problems is still a major research focus in the development of microRNAs delivery vectors in the future. Nonetheless, microRNAs are an exciting area of research because of their unique regulatory mechanisms and therapeutic potential in AS. It is hoped that continued clinical research and technological advances will shed light on these unresolved questions and advance the practical application of microRNAs as therapeutics for cardiovascular diseases.

8. Conclusions

MicroRNAs play important roles in AS development. We elucidate and summarize the recent studies on microRNAs regulation of the functions of endothelial cells, vascular smooth muscle cells, macrophages, and cholesterol metabolism in AS. MicroRNAs have the potential to be a novel diagnostic biomarker and therapeutic targets for atherosclerosis in the future.

Data Availability

The data used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

L.Z. prepared the manuscript and drew charts. S.S. and Z.Y. drew charts. S.R. reviewed the manuscript. All authors have read and approved the final manuscript.

Acknowledgments

Authors would like to appreciate all authors who participated in this study. This work was supported by the Macau Science and Technology Development fund (FDCT 0007/
References


